The pulmonary circulation and the mechanisms which generate pulmonary hypertension are reviewed. The role of these mechanisms in the common pulmonary hypertensive states are analysed, particularly those in acute lung injury. Management options are discussed, with particular emphasis on the use of selective pulmonary vasodilators.
The acute respiratory distress syndrome (ARDS) and disorders such as persistent pulmonary hypertension of the newborn (PPHN) are characterized by pulmonary hypertension (PHT) 1,2 and severe hypoxaemia 3 . Little progress has been made in providing effective therapy for these conditions and mortality remains high 5 . Selective pulmonary vasodilators (SPV) have recently addressed one aspect of these disorders, the PHT, which might now be more amenable to therapy.
THE PULMONARY CIRCULATION
The pulmonary circulation is a low-resistance system which can accommodate passage of the normal cardiac output (CO) at a typical pressure of 20/12 mmHg 6 . A pressure drop of 5 to 10 mmHg is sufficient to move a CO of 5 to 6 l/min from pulmonary artery to left atrium under resting conditions 6 . This is in marked contrast to the systemic circulation where the pressure drop for the same flow may be as much as 80 mmHg 7, 12 . Even during exercise, when CO may rise from 6 l/min to 25 l/min, pulmonary artery pressure (PAP) rises by only a few mmHg 6, 7 .
PHT is generally defined as a mean pulmonary artery pressure (MPAP) greater than 20 mmHg 14 (or alternatively when systolic and diastolic pressures exceed 30 and 10 mmHg respectively). These pressures normally increase with age and altitude 6 . Pulmonary vascular resistance (PVR) is defined as the ratio of pressure drop across the circuit to the flow through the circuit, and has proven to be a useful concept in assessment of the pulmonary circulation 7 .
The pulmonary circulation has some unique characteristics that counteract PHT. There is a large amount of elastic tissue and a relatively small amount of smooth muscle in the arteries and large arterioles (with no smooth muscle in small veins and arterioles) 6 . These vessels therefore have great distensibility and are able to act as capacitance vessels. In conditions of increased flow, distension plays a major role in preventing a pressure rise in patent vessels 8 . This is particularly true in the capillary bed. In addition to this mechanism, previously closed capillaries lying in the alveolar septa are recruited when flow increases, limiting pressure rises 9 . The pulmonary circulation is thereby protected against an increase in flow. For example, following pneumonectomy, the remaining lung is able to accommodate the entire CO without an increase in pressure 7 . However, PA pressures are dependent not only on flow, but also on PVR, and PHT will result when PVR is increased.
There are multiple factors which influence the pulmonary circulation in general and PVR in particular.
Hypoxia
Hypoxia exerts a vasoconstrictor effect (hypoxic pulmonary vasoconstriction-HPV) which will be dis-cussed in detail below. The effect is mediated both by the alveolar partial pressure of oxygen (P A O 2 ) and by the mixed venous partial pressure of oxygen (P V O 2 ) 7 . The relationship is non-linear.
Hypercapnia
Hypercapnia exerts a slight vasoconstrictor effect.
Autonomic Innervation
Pulmonary vessels have both sympathetic and parasympathetic innervations, principally on the arterial side of the circulation. Their influence under resting conditions is not as strong as the corresponding innervation of the systemic circulation, as there is little smooth muscle to exert a vasomotor effect. α-Adrenergic nerve endings are vasoconstrictor and β-adrenergic nerve endings are vasodilator. The parasympathetic system is vasodilator, mediated by acetylcholine.
Lung Inflation
Lung inflation is thought to have a dual effect on PVR-expanding large vessels by traction while collapsing smaller ones. It has been shown that the vessels in collapsed alveoli do not constitute a mechanical obstruction to flow 10 .
Posture
Perfusion is distributed down a vertical gradient in the lung reflecting the balance between intra-alveolar pressure (which is sufficient at the apices to prevent flow) and the distending vascular pressure (which is sufficient at the bases to ensure continuous flow) 11 . Flow is also affected by factors such as posture and right ventricular pressures 14 .
When PVR is elevated by one or more of the above factors, the compensatory mechanisms of distension and vessel recruitment may be less effective. Increased flow will then result in PHT. The right ventricle (RV) may not be able to maintain flow against the elevated afterload and may fail 12 . PHT then, has important pathological sequelae.
The ability of the pulmonary vasculature to control the distribution of blood flow within the lung is limited. Also, gravity has a marked effect on distribution, resulting in relative overperfusion of dependent parts of the lung. Ventilation is also non-uniformly distributed within the lung, being relatively greater at the base than the apex in the erect subject, but the degree of maldistribution is less than for perfusion 13, 14 . Consequently there is a spread of ventilation/ perfusion (V . / . Q) ratios through the lungs, ranging from about 0.5 at the base (i.e. relative shunt) to 2 at the apex (i.e. relative deadspace) in healthy subjects (Figure 1) (p. 32). The spread of . V/Q . ratios has important implications for gas exchange, discussed in more detail below.
AETIOLOGY OF PULMONARY HYPERTENSION
PHT results from a multitude of aetiologies ( Table  1 ) and by several different mechanisms. Most PHT is secondary to chronic pulmonary or cardiovascular disease. Primary PHT (PPH) is a disorder in which PAP is elevated in the absence of any demonstrable cause and accounts for a small proportion of cases.
PHT may also be classified on the basis of the anatomical site of the increased resistance to flow 12 . In left ventricular failure or valvular heart disease, a decrease in forward flow from the left ventricle elevates post-pulmonary capillary pressures, which requires an increased upstream pressure to maintain circulation. The gradient between PAP and left atrial pressure (LAP) or pulmonary artery occlusion pressure (PAOP) remains small. In contrast, in conditions in which the resistance to flow is mainly in pulmonary arteries or arterioles (such as primary PHT), there is an increased arteriovenous gradient. In pulmonary veno-occlusive disease there is obliteration of small and medium-sized pulmonary veins, but the PAOP remains normal. This occurs because the process is 27 
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Anaesthesia and Intensive Care, Vol. 26, No. 1, February 1998 patchy, and flow is preferentially distributed down unaffected vessels. PAOP reflects downstream pressure and will be measured as normal in the unaffected vessels. The capillary bed is not usually involved in pathological processes which result in PHT except in the rare disorder, pulmonary haemangiomatosis. Pathophysiological mechanisms that contribute to the development of PHT are hypoxia, loss of or mechanical distortion of vessels, obstruction of vessels by thrombus and polycythaemia 6 . In most cases of PHT several of these mechanisms are operating.
PRIMARY PULMONARY HYPERTENSION
PPH is a disorder in which PHT is present without an apparent cause. The condition is rare, prognosis is poor, and diagnosis is made by exclusion of other causes 6, 15 . Three criteria are required 6 ; PHT is apparent on clinical, radiological, and electrocardiographic grounds; right heart catheterization shows an elevated PAP with a high PVR, but normal PAOP and low CO; and no cause for PHT is evident. The mechanism seems to be an abnormal proliferative response in the small muscular arteries in response to an unknown stimulus that results in widespread vascular obstruction 16 . Histological examination shows characteristic changes in both media and intima, as well as evidence of inflammation 12, 16, 17 .
SECONDARY PULMONARY HYPERTENSION 1. PHT in Cardiac Disease
Cardiac disease causes PHT by either increasing pulmonary blood flow (i.e. by left-to-right shunting) or by increasing pulmonary venous pressure. In leftto-right shunting (e.g. septal defects), pulmonary flow may be several times normal, but this, per se, does not usually raise PAP significantly (unless the increase in flow is very marked 12 ) due to the compensatory mechanisms of distension and vessel recruitment (see above). However, in the patient with acute increase in flow, this may not be the case 12 . Alternatively, in the patient with sufficient pulmonary parenchymal disease to cause hypoxaemia, HPV contributes to the development of PHT, as does the polycythaemia of chronic hypoxia 6, 12 . It has also been suggested that chronic distension of vessels in the setting of left-toright shunting may itself act as a stimulus to vasoconstriction 12 . Whatever the mechanism, increased flow in the setting of an elevated PVR has the pathophysiological consequences outlined above; compen-satory mechanisms fail, and PHT and RV failure ensue.
In the case of pulmonary venous hypertension (the usual cause being left ventricular failure), longstanding venous hypertension requires an increased upstream pressure to maintain flow; this almost invariably leads to pulmonary arterial intimal proliferation and vascular remodelling. Such a process is well documented in the systemic circulation. Perivascular fibrosis occurs and sustained arterial hypertension results 12, 14 . Small vessel emboli also predispose to the development of PHT. Embolic phenomena may be seen when the RV fails and CO is reduced.
PHT in Pulmonary Thromboembolic Disease
In developed nations, pulmonary thromboembolus (PTE) is a common cause of PHT. In developing nations, other causes of PHT are predominant; for example, schistosomiasis in Egypt, and filariasis in India. The PTE syndromes can be classified according to which segment of the pulmonary vasculature is affected; small, intermediate or large arteries 6 .
Small vessel disease, in which small arteries and arterioles are involved, was once thought to be caused by showers of small emboli, but it is now understood that the vessels are occluded by organized thrombus. PHT arises from loss of the cross-sectional area available for blood flow. The syndrome is rare and commonly misdiagnosed as PPH.
The commonest scenario is occlusion of arteries of intermediate size by embolus. Such emboli generally originate from lower limb vessels and are often recurrent and multiple. The defects in perfusion are demonstrated by . V/Q . scanning and angiography. PHT arises acutely, both from loss of cross-sectional area (although over 50% of vessel area must be lost before a significant change in pressure is seen) and from HPV secondary to . V/Q . mismatch. The role of humoral influences remains controversial, but they probably do play a role in generation of PHT. Most, but not all thromboemboli, resolve and the patient does not develop fixed PHT 20 . Variations in the efficacy of fibrinolytic mechanisms, and the degree of organization of clot which occurs may explain why only some patients develop chronic disease. Alternatively, recurrent emboli are a cause of chronic PHT 19 .
The majority of survivors of massive proximal vessel PTE survive because of clot resolution, in which case chronic PHT does not occur 20 . PHT occurs in the acute situation as with smaller pulmonary thromboemboli. In a few instances clot can become incorporated into the vessel wall with organization, endothelialization, and both retrograde and antegrade propagation 19 . Chronic PHT may then result. Often this diagnosis is made late, which is unfortunate as early surgical intervention with endarterectomy can be curative, although haemodynamic improvement can still be obtained after several months 21 .
PHT in Respiratory Failure
There are several mechanisms by which respiratory disorders elicit PHT 22 . For example, fibrotic or inflammatory disorders cause microvascular narrowing, leading ultimately to occlusion of vessels. Crosssectional area available for flow is reduced, and, at the same time, remaining vessels are less distensible. In airflow limitation, . V/Q . mismatch causes hypoxaemia and reflex vasoconstriction. In asthma and emphysema, vessels are compressed by hyperexpanded lungs and in emphysema, destruction of parenchyma leads to concomitant loss of vessels. In hypoventilation syndromes, chronic hypoxia causes chronic pulmonary vasoconstriction, and eventually, fixed hypertension 23 . In chronic respiratory failure several mechanisms may operate together.
Hypoxic Pulmonary Vasoconstriction
Alveolar hypoxia is a common feature of many respiratory disorders, and a major contributor to development of PHT 22, 24 . Hypoxia in the alveolus produces a vasoconstrictor effect-hypoxic pulmonary vasoconstriction (HPV)-on the local pulmonary circulation, the opposite of its effect in the systemic circulation 27 . HPV has the beneficial effect of diverting blood flow away from regions where the oxygen tension is low and thereby optimizing . V/Q . matching 8 . As we have seen, . V/Q . inequalities exist even in the normal lung, and mismatch is increased in pathological states 25 . HPV therefore serves as an important mechanism to maintain oxygenation in respiratory failure.
The vasoconstrictor response to hypoxia occurs mainly in small arterioles of about 200 µm diameter, although it is also seen in larger arteries at low oxygen tension 18 . These smaller vessels are in very close relation to the small bronchioles and alveoli, which ensures rapid detection of alveolar hypoxia 26 . There are two major theories as to how alveolar hypoxia may bring about pulmonary vasoconstriction 27 . First, alveolar hypoxia may cause release of a vasoconstrictor substance. No such substance has been identified and there is now a reasonable amount of evidence [28] [29] [30] that the response is mediated by decreased production of nitric oxide (NO), a pulmonary vasodilator, although the exact role of NO is not yet clear. The second possibility is that hypoxia may stimulate cellular metabolism in vascular smooth muscle in such a way as to influence excitation-contraction coupling and directly cause vasoconstriction 26 . The two mechanisms are not mutually exclusive.
Other mechanisms also contribute to PHT in the chronic forms of respiratory failure 22 such as increased blood viscosity due to polycythaemia, and PTE. Several of these mechanisms are usually operating in chronic respiratory disease. HPV is often the major contributor in acute respiratory failure 31 , which will be discussed below.
PHT and Acute Lung Injury
Acute respiratory failure is commonly seen in the critically ill patient and results from a diffuse injury to lung parenchyma 4 . The spectrum of disease that results was initially termed ARDS 32 but is now called acute lung injury (ALI), of which ARDS is the most severe form 3 . The earliest abnormality of ALI is increased endothelial permeability which results in interstitial pulmonary oedema 33 . This soon accumulates to the point where the lymphatics are overwhelmed and alveolar oedema occurs (the exudative phase). Early in the course of disease type I alveolar epithelial cells are lost; parenchymal elasticity is reduced and the basement membrane is exposed. Lung compliance falls and atelectasis ensues. Later, type II alveolar epithelial cells are damaged; a dysfunctional proliferative response is seen (the proliferative phase) and surfactant deficiencies compound the process of alveolar collapse and flooding. It is this sequence of events which causes the refractory hypoxaemia characteristic of ALI [34] [35] [36] .
However, the above is not the only mechanism operating; it has been shown that the degree of hypoxia in ALI bears little relation to extravascular lung water, although microvascular permeability may be related 37, 38 . At least some of the hypoxia is due to oedema-independent alterations in . V/ Q . matching. Shunting of blood from injured vascular beds to relatively normal ones (HPV) is a critical protective mechanism in the normal or in the regionally injured lung 35 . HPV is particularly evident in the acute situation when acidosis and hypercarbia, both of which potentiate pulmonary vasoconstriction, are often present. However, in the diffusely injured lung, the protective vasoconstrictor response can create an inappropriate state of widespread increase in vasomotor tone and increase PVR significantly 39 . The stimulus for inappropriate HPV appears to be not only hypoxia, but also release of vasoactive mediators, such as platelet activating factor (PAF), tumour necrosis factor (TNF) and interleukins 1, 6 and 8 31, [40] [41] [42] . These mediators are released from the endothelium as part of an uncontrolled systemic inflammatory response common in the critically ill 43 . One of the many effects is to cause platelet aggregation in the microcirculation and leucocyte adhesion to endothelium. Coagulation follows, and vasoconstriction is also stimulated as part of the coagulation process. The tendency to microvascular thrombosis is enhanced by depressed fibrinolysis, and the net result is a marked increase in PVR.
MANAGEMENT OF PHT ASSOCIATED WITH ACUTE LUNG INJURY
Treatment of PHT in the patient with ALI is a worthwhile goal for several reasons. PHT contributes to pulmonary oedema and can cause RV dysfunction 44 . Furthermore, marked elevations in PVR are associated with a poor outcome 45 . Lowering PAP and the effective pulmonary capillary pressure improves RV function and possibly promotes resolution of pulmonary oedema 46, 47 .
Until recently the therapy for PHT has been largely empirical. The mainstays of treatment have been maintenance of oxygenation and vasodilator therapy. Polycythaemia is rarely severe enough to be a serious problem, although isovolaemic phlebotomy to a haematocrit of 50-55% may decrease hyperviscosity without decreasing tissue oxygen delivery 48 . Attempts to improve pulmonary circulation with cardiotonic agents (digoxin) 49 and anticoagulation (warfarin) have not met with marked success. Prophylactic anticoagulation has been advocated for patients with chronic PHT 50 . Anticoagulation is not without risk and life-threatening adverse effects may occur.
Oxygen Therapy
Because hypoxia is a major contributor to both acute and chronic PHT, correction of hypoxia is an important component of management. Patients with ALI gain only partial relief of hypoxia from delivery of a high fraction of inspired oxygen (FiO 2 ) 39 . This is because the problem is one of intrapulmonary shunt and venous admixture 51 . Various interventions are used as adjuncts to oxygen therapy with the intention of improving oxygenation while minimizing the toxic effects of a high FiO 2 . These include manipulations of intravascular volume, CO and levels of applied positive end-expiratory pressure (PEEP). Careful titration of these variables to elevate oxygen delivery (DO 2 ) to supranormal levels has been suggested as a strategy to improve outcome in the critically ill postoperative patient 53 and in septic shock 54 , although there is recent evidence to the contrary 55 . The specific effect of correcting hypoxia on haemodynamic performance is difficult to define in isolation. Certainly, in early ALI, most of the increase in PVR can be abolished by perfusing the lungs with oxygenated blood 56 , suggesting that HPV is responsible for the PHT. Later, when histological changes of fibrosis and vascular remodelling have occurred, the defect is not so readily reversible. Accordingly, manipulation of haemodynamic and respiratory variables to achieve optimal oxygenation is crucial early in the management of ALI, before the oxygen transport problem becomes of sufficient duration to bring about fixed PHT.
Vasodilator Therapy
Although vasodilator therapy may lead to haemodynamic and symptomatic improvement in patients with chronic PHT, the effect is not universal, may not be sustained and there may be significant sideeffects 12, 14 . Therapy must therefore be individualized and patient response monitored carefully. Various agents have been used as vasodilators in both primary and secondary PHT. These include α-adrenergic antagonists 57 , β-adrenergic agonists 58 , diazoxide 59 , hydralazine 60 , nitrates including NO, angiotensinconverting enzyme inhibitors 62 , calcium channel blockers 52, 63 , prostaglandins, phentolamine 64 and adenosine 61, 65 .
The ideal pulmonary vasodilator would decrease RV afterload while increasing CO and systemic oxygen delivery. To achieve these goals a substantial decrease in PAP would need to occur while stroke volume (SV) and systemic arterial pressure (SAP) remained unchanged. This combination of haemodynamic goals has proven difficult to achieve with systemically administered vasodilator agents. In patients with PPH undergoing right heart studies and vasodilator testing prior to longterm therapy, the "ideal" response is seen in only 25-30% of patients 66 . However, when achieved, the "ideal" response is associated with regression of right heart abnormalities 67 and improved survival 68 .
Although vasodilators can decrease PHT when administered systemically, their clinical usefulness is limited by their non-selectivity. There is a twofold requirement for selectivity. Agents should be selective for the pulmonary circulation as opposed to the systemic and so avoid systemic hypotension. They should also be selective for well-ventilated alveoli as opposed to poorly ventilated alveoli, thereby avoiding increased right-to-left shunt, venous admixture and worsening oxygenation. Several trials of intravenously infused agents (including agents infused directly into the pulmonary artery) have demonstrated that reductions in PAP can only be gained at the expense of systemic hypotension, with the concomitant risks of RV ischaemia and heart failure [69] [70] [71] [72] [73] [74] [75] . Furthermore, increased flow to the areas of poor ventilation induced by systemic vasodilators worsens . V/Q . mismatch, and has been shown to reduce the already compromised P a O 2 . The use of systemic vasodilators in ALI has therefore largely been abandoned. A notable exception is adenosine. Adenosine is a synthetic purine nucleoside. It is not absorbed orally, and is used intravenously as an antiarrhythmic agent.
There are now several studies describing its use as a pulmonary vasodilator in PPH 61, 65 . Because of its extremely short half-life it does not have a significant effect on the systemic circulation and has been shown to improve pulmonary haemodynamics when infused into a central vein in cardiac surgical patients 61 .
Selective Pulmonary Vasodilators

Nitric Oxide (NO)
The emergence of NO as a therapeutic agent in 1987 has stimulated intense research into its potential use as a selective pulmonary vasodilator (SPV). Although it is not licensed for use in Australia, over 14,000 research papers have been written on NO in the last five years and it has become accepted for use as a SPV in certain circumstances.
NO is a gaseous, endothelium-derived smooth muscle relaxant which plays a key role 76 in maintaining a basal level of systemic and pulmonary vascular relaxation as well as acting as an inflammatory mediator, a signalling molecule and a mediator of host defences [77] [78] [79] [80] [81] [82] [83] . NO is an ideal transcellular messenger as it has a short half-life, and is a small lipophilic molecule which diffuses easily across membranes. It activates guanylate cyclase 84 by binding to the heme iron moiety of the enzyme, and thereby stimulates production of cyclic GMP (c-GMP). In smooth muscle, c-GMP activates a protein kinase which reduces intracellular calcium concentrations, decreasing muscle contractility.
Exogenous NO dilates the pulmonary vasculature when inhaled at low concentration 30, 85 , and is rapidly inactivated by binding to haemoglobin in the pulmonary circulation 86 . It is therefore devoid of systemic effect. Also, because it is delivered to ventilated lung, it has the effect of increasing blood flow in proportion to ventilation 87 . The dual requirements for selectivity are thereby fulfilled. NO has several functions apart from its vasodilator action. A bronchodilator effect has been demonstrated in animal studies and in humans with methacholine-induced bronchospasm, although the effect may not be as marked in man 88 . It is a neurotransmitter in both central and peripheral nervous systems 79, 89 and plays a role in macrophage toxicity 77, 79 . Other functions include regulation of leucocyte adhesion 90 , platelet aggregation 79 and smooth muscle proliferation 91 . Of particular interest is the observation that PHT in ARDS is associated with impaired production of NO. The relevance of this observation is still uncertain, but it adds weight to the rationale for use of NO in ARDS.
Inhaled NO has been shown to be an effective SPV in several clinical settings. The first report of its use to decrease PAP was in 1988, when Higgenbottam and co-workers reported that inhalation of NO decreased PAP in patients with PPH 93 . The idea was subsequently developed at a number of centres, working initially with animal models, including PHT induced by hypoxia 30 , vasoconstrictor administration (e.g. NO synthase inhibitors) 94 , endotoxin administration 95 , the heparin-protamine reaction 85 and ALI 96 . PHT was reversed without adverse systemic consequences in the majority of these models, confirming its potential as a SPV. In particular, the work of Fratacci et al 85 Simultaneously, other investigators have reported the use of NO in adults with chronic PHT 101 , cardiac failure 102 , reactive airways 88 , and both preoperatively 92 and perioperatively in cardiac surgery 103 . In the paediatric population, success has been reported in ARDS 104 , in PPHN 105 , and in children with congenital heart disease and perioperative PHT 106 . The focus has now shifted to establishing dose-response relationships and investigating potential toxicity [107] [108] .
The initial work on NO has been done with doses ranging from 1 109 to 128 99 
parts per million (ppm).
Recently, there is evidence that much lower doses of NO, in the parts per billion (ppb) range, can be equally efficacious. Using doses of between 60 and 31 SELECTIVE PULMONARY VASODILATORS 230 ppb Gerlach et al have demonstrated significant improvement in oxygenation and decrease in shunt fraction without change in pulmonary resistance 110 .
Others have also noted that the doses of NO required to improve oxygenation are much lower than the doses required to diminish PVR and PAP 98, 100 . This suggests that the dose-response curve for pulmonary artery pressure may not be the same as that for oxygenation, and that the beneficial effect of NO on pulmonary perfusion is due to a redistribution effect, rather than pure enhancement of flow. Concentrations as low as those used by Gerlach approach the level found in room air (usually around 10 ppb although levels in expired air can reach 250 ppb) 111 and must be regarded as non-toxic. However, further work on dose-response is required. In most cases, in adults, concentrations of 5-40 ppm are sufficient to lower PAP 111 .
The response to NO is not entirely predictable. Several studies have now documented groups of critically ill patients with ALI who have not responded to low-dose NO (<40 ppm) 87, 112, 113 , although the definition of response has varied substantially. The mechanism of this variability in response is not known, although the degree of initial PHT appears to correlate with the likelihood of response, those patients with the most marked PHT being most likely to benefit 99, 112 .
Withdrawal of NO therapy has also proven to be problematic in patients with ALI and PHT. Sudden worsening of PHT and consequent hypoxaemia has been reported on cessation of therapy 112, 114 . Again, this is an unpredictable phenomenon and the mechanism is not known. It may be due to suppression of endogenous NO production by exogenous administration (product inhibition), or to release of a vasoconstrictor substance.
The toxicity of NO remains an area of active research. It reacts with oxygen to form strong oxidants with as yet incompletely understood effects on normal and pathological cellular metabolism. The rate of oxidation is dependent on the oxygen concentration and the square of the NO concentration 115 . At high concentrations, NO causes marked methaemoglobinaemia and has caused death 116 . At lower concentrations, the avid binding to haemoglobin may protect the systemic circulation from toxicity, but the pulmonary circulation and alveoli remain at risk.
In general, levels of methaemoglobin reported during administration of NO have been less than 5% which is not thought to be clinically significant [117] [118] . Higher levels have been reported during administration of NO to neonates 119 . Few other direct toxic effects exist. The clinical significance of the finding that NO causes reduced platelet adhesion is not clear 109 . Bleeding time is prolonged in volunteers administered NO 121 , but there are no reports of coagulation problems with NO in clinical use. Most studies have not addressed the issue of longterm NO administration, or the potential for accumulation over prolonged periods of therapy, although there is a study reporting administration to infants for periods of up to several weeks without adverse effect 104 . In adults with PPH, NO has been administered in a pulsed fashion over periods of up to nine months, again without adverse effect 120 .
In contrast, the higher oxides of nitrogen are known to be toxic substances. Nitrogen dioxide (NO 2 ) has considerable pulmonary toxicity, causing pneumonitis and pulmonary oedema, and has been reported as a cause of cytotoxicity and death in experimental animals [122] [123] . NO 2 is metabolized to nitrous and nitric acids in aqueous solution, and a number of other higher nitrates and nitrites are formed with as yet unknown effects 124 . Metabolism of NO to NO 2 is therefore a potential hazard, and NO and NO 2 monitoring are mandatory during use of NO, as is adherence to national guidelines for safe levels of both compounds. Scavenging with soda lime has been advocated, but whether this is an effective technique for removing the higher oxides from the circuit has been questioned 125 . With or without scavenging, NO should be monitored so that ambient levels are less than 25 ppm, and NO 2 less than 1 ppm 81, 126 .
Apart from potential toxicity, the other major problem with administration of NO is the delivery system required for its use. This topic has been recently reviewed 127 and a number of systems are described (Figure 1) 119, [128] [129] [130] . All aim to deliver a known concentration of NO to inspired gas while minimizing the time available for reaction with oxygen to form higher nitrates. A final consideration is the capital outlay necessary in order to administer NO. As well as the cost of the delivery system, the monitoring and safety equipment must be funded and, although NO gas itself is not expensive, the cost of administration is significant.
Prostacyclin
Prostacyclin (PGI 2 ) is a member of the prostaglandin family of lipid mediators derived from arachidonic acid. It is the main product of arachidonic acid metabolism in all vascular tissues studied so far 131 . Endothelial cells produce most PGI 2 (although it is also synthesized by smooth muscle cells) and synthetic ability declines from intima to adventitia [131] [132] . PGI 2 is the most potent endogenous inhibitor of platelet aggregation yet discovered, and has also been shown to disperse platelet aggregates and inhibit thrombus formation 74, [133] [134] [135] . These effects are achieved by activation of intracellular adenylate cyclase, which is initiated when PGI 2 binds to a specific cell-surface receptor 135 . Adenylate cyclase catalyses production of cyclic AMP which activates a protein kinase, and decreases intracellular calcium levels. PGI 2 is also a potent vasodilator in all vascular beds including the pulmonary circulation 134, [136] [137] [138] . The physiological role of prostacyclin is to maintain endothelial nonreactivity to platelets by inhibiting thrombus formation (while maintaining the capacity for vessel wall repair) 131 , and to maintain a low vascular resistance in beds such as the pulmonary circulation 139 , where its secretion is increased by hypoxia 140 . It also stimulates endothelial release of NO 141 , raising the possibility of a synergistic interaction between the two agents. This does not seem to be the case however, with respect to vasodilator properties 142 . Disorders of PGI 2 production have been implicated in PHT although the significance of these observations remains uncertain [143] [144] . PGI 2 has a short half-life (2 to 3 mins) and few side-effects. Catabolism of PGI 2 begins with its spontaneous hydrolysis in plasma to 6-keto prostaglandin F 1α ). A number of oxidative steps follow, giving rise to a vasoconstrictor metabolite, 6-keto prostaglandin F 2α (6-kPgF 2α ) 145 . These reactions occur mainly in the liver and the inactive compounds are excreted in the urine. PGI 2 metabolites can be measured using standard radioimmunoassay techniques (6-keto prostaglandin F 1α , H-RIA-Kit, Advanced Magnetic, Cambridge, MA, U.S.A.) [146] [147] .
PGI 2 was first used intravenously as a pulmonary vasodilator in 1978 133 . Since that time it has been used as a pulmonary vasodilator for a number of condi-tions in an increasing number of centres. Intravenously, its use has been reported in animal models of PHT 75, 148 , and in humans with conditions including PPH [149] [150] [151] , ARDS [46] [47] 73 , peripheral vascular disease 152 , heart failure 153 , sepsis 154 and in patients after heart transplant 155 . Varying degrees of success are reported, according to the condition being treated. PGI 2 has also been used intravenously to assess whether established PHT will respond to vasodilator therapy 60 .
In PPH, a beneficial effect has been shown in several trials [149] [150] [151] . Symptomatic and haemodynamic improvement was reported in 1990 150 , and a survival benefit was demonstrated in 1993 151 . Trials in cardiac failure have failed to demonstrate reduced mortality 153 , but there may still be a place for the drug in the acutely decompensating patient in whom an agent with a short half-life, minimal toxicity and no tendency to develop tolerance is required. Similarly, PGI 2 finds a role in pulmonary hypertensive crisis following cardiac surgery 156 .
In the setting of ALI, several trials have demonstrated that the use of intravenous PGI 2 is limited by dose-dependent systemic vasodilation, leading to hypotension, and by increased venous admixture especially when administered by continuous infusion. Increased venous admixture diminishes arterial oxygen content, and the overall effect of PGI 2 on oxygenation is therefore dependent on the ability of the drug to increase oxygen delivery by raising CO 147 . Radermacher et al 46 demonstrated a decrease in PAP in patients with ARDS, associated with a fall in systemic pressure and a rise in CO. Overall, there was little net effect on oxygenation, as there was a marked deterioration in . V/Q . matching. The same group subsequently demonstrated improved RV function with PGI 2 in a similar setting 47 . Other investigators have had similar results 87, 154 . The lack of a beneficial effect on oxygenation and the emergence of NO as a selective agent prompted research into PGI 2 administration via the inhaled route.
The use of PGI 2 via the inhaled route (inhaled aerosolized prostacyclin-IAP) was first reported in 1978 134 . The successful use of IAP as a SPV was again reported in 1984 74 . A canine model of HPV was described in 1993 in which administration of IAP led to a reversal of HPV and a decrease in PAP without systemic consequences 147 . A trial in three patients with ARDS reported favourable effects on MPAP and improved oxygenation, again without systemic effect 157 . In contrast to intravenous PGI 2 , IAP does not increase CO, and therefore the decreased PVR observed in these studies should truly reflect changes in the pulmonary vascular tone 147 .
Subsequent to this early work, an animal trial using a canine HPV model compared IAP with NO. Reduced RV afterload and oxygen demand was demonstrated for both agents, with only minor changes in SV and CO, suggesting improved RV performance 158 . A similar trial in piglets with thromboxane-induced PHT showed both agents significantly decreased PAP without any effect on MAP. Shunt fraction was improved and a beneficial effect on oxygenation was noted 148 . In humans, a comparative trial in children with ARDS found that both NO and PGI 2 acted as SPVs, decreasing PAP without systemic effect, leading to improved oxygenation 159 . A number of case reports have demonstrated the effectiveness of IAP for PHT and severe hypoxaemia in both neonates [160] [161] and in older children 162 . In adults, Walmrath et al demonstrated beneficial effects on PHT and oxygenation in patients with severe pneumonia 163 . There are also a number of case reports, again demonstrating beneficial effects on PHT and oxygenation [164] [165] [166] . A clear dose-response relationship was seen in one patient 166 . The author has compared NO (10 ppm) and IAP (50 ng/kg/min) in patients with ARDS and found the two agents to be comparable as SPVs in this setting 167 . This correlates with a similar study by Walmrath et al 168 . All reports so far are agreed that prostacyclin acts selectively and is at least as effective as NO.
The main advantages of IAP over NO are ease of administration and lack of toxicity. Nebulization is a technique universally available and the equipment necessary for administration is minimal. A syringe driver pump is required which delivers a known concentration of drug to a nebulizer bowl. Nebulization is then powered by a gas flow of 6 l/min. The equipment set-up as illustrated in Figure 2 has been used in most studies to date and had proved both simple and effective.
The amount of drug deposited in the alveolus by such apparatus remains an area of uncertainty. A distal site of deposition is inferred from a knowledge of the particle size delivered and from the clinical effect observed. To achieve distal deposition a particle must be of size 0-5 µm 158 . Particle size has been measured in some of the reports in the literature and appropriately sized particles have been delivered in varying proportions, between 21% 158 and over 70% 166 . Even with appropriately sized particles, the amount of a nebulized drug which actually reaches the alveolus in a ventilated patient is known to be a small fraction (less than 10%) of the total amount administered [169] [170] [171] .
As regards toxicity, systemic haemodynamic sideeffects (hypotension, tachycardia) have not been seen with IAP. PGI 2 is not transformed into an active form in the lung, nor is it significantly metabolized 172 . Arterial concentrations of its major metabolite, 6-keto prostaglandin F 1α have usually been unchanged during inhalation of PGI 2 [146] [147] , although a recent report from our institution describes a case in which there was a rise. The major area of concern has been the effect of IAP on coagulation. Intravenous PGI 2 has been shown to lead to a dose-dependent inhibition of platelet aggregation and dispersal of thrombus, with preservation of platelet number and function 74, [133] [134] [135] . However, there has been no report of any adverse effect on coagulation using PGI 2 via the inhaled route. No other systemic toxic effects have been described. PGI 2 has been reported as being irritant to the airway when administered intratracheally [173] [174] . A final area of concern is the alkalinity (pH 10.5) of the glycine buffer medium in which PGI 2 is prepared. There is one report of the effect of this agent on respiratory mucosa 146 , but as with NO, this and other potential toxicities are the subject of ongoing research.
Prostacyclin Analogs
The emergence of PGI 2 as a useful therapeutic agent has stimulated a research effort into design and synthesis of analogs with desirable physicochemical profiles. These include iloprost, cicaprost and beraprost [175] [176] [177] .
Iloprost is a stable carbacyclin derivative of PGI 2 . Like PGI 2 , it is found chiefly in vascular endothelium and has been shown to have similar effects on intracellular cAMP levels. Platelets and neutrophils exhibit in vitro responses to iloprost similar to PGI 2 , and the two agents are reported to have identical efficacy when used as pulmonary vasodilators. It has also been shown to be beneficial in peripheral vascular disease. Iloprost, being the more stable compound, has a longer duration of action when administered by the inhaled route.
Beraprost 178 has been tried orally in a small number of patients with PHT. It was successful in reducing PAP and improving cardiac index in a short-term study, and improved NYHA functional class in a longterm study. Minor side-effects were common but no significant haemodynamic disturbance was reported.
Potential advantages of these PGI 2 analogs over PGI 2 include their solubility in saline, obviating the need for the highly alkaline buffer and the associated concerns regarding the toxicity of the buffer in which PGI 2 is prepared, and a lower viscosity which facilitates nebulization. None of these agents is commercially available for use in Australia. To date, only iloprost has been evaluated clinically to any extent. No cost analysis is available, and there are few controlled trials comparing the newer analogues with IAP or NO. Their clinical efficacy remains unknown, and they are regarded as investigational agents.
CONCLUSION
The advent of NO and more recently of IAP has provided clinicians, for the first time, with an opportunity to effectively treat the PHT characteristic of ALI, without major adverse effect. The importance of such therapy lies in its potential implications for outcome improvement, an area in which there has been little progress since ARDS was first described. Good evidence now exists that both NO and IAP act as selective pulmonary vasodilators, and their administration results in beneficial effects on haemodynamic performance and on oxygenation. The challenge for the future will be to define optimal use of these agents. For NO the main issues to be resolved are whether very low-dose NO is appropriate, and how best to prevent the toxic effects of the higher oxides. A simple delivery system is also needed. For IAP the main issues are defining a dose-response relationship, and ongoing documentation of its efficacy in the clinical setting, particularly compared with NO, the established agent. We can expect to see other vasodilators investigated for use in the same way; and although it is premature to hail either agent as a "magic bullet" the direction for future research is clear. The utility of selective pulmonary vasodilators is established. The remaining questions are ones of efficacy, ease of administration, safety profiles and cost.
